|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,613.20 INR | -3.71% |
|
-7.17% | -6.29% |
Evolution of the Average Target: Sun Pharmaceutical Industries Ltd.
Evolution of the Target Price: Sun Pharmaceutical Industries Ltd.
Changes in Analyst Recommendations: Sun Pharmaceutical Industries Ltd.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +17.3% | |||||
| -7.87% | |||||
| +11.83% | |||||
| +17.87% | |||||
| +15.03% | |||||
| - | +15.34% | ||||
| -12.78% | |||||
| -19.77% | |||||
| +10.5% | |||||
| Average | +5.27% | |||||
| Weighted average by Cap. | +7.46% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Nomura | |
| Jefferies & Co. | |
| Avian |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUNPHARMA Stock
- Consensus Sun Pharmaceutical Industries Ltd.
Select your edition
All financial news and data tailored to specific country editions
